tiprankstipranks
Trending News
More News >
Australian Clinical Labs Ltd (AU:ACL)
:ACL
Australian Market
Advertisement

Australian Clinical Labs Ltd (ACL) AI Stock Analysis

Compare
58 Followers

Top Page

AU:ACL

Australian Clinical Labs Ltd

(Sydney:ACL)

Rating:69Neutral
Price Target:
AU$3.00
â–²(6.38%Upside)
The overall stock score of 69 reflects a balanced view of the company's financial health and valuation. The financial performance is the key factor, with declining revenue and high leverage as concerns, yet strong cash flow provides stability. Technical indicators suggest a neutral market position, while the valuation appears reasonable with an appealing dividend yield.

Australian Clinical Labs Ltd (ACL) vs. iShares MSCI Australia ETF (EWA)

Australian Clinical Labs Ltd Business Overview & Revenue Model

Company DescriptionAustralian Clinical Labs Ltd (ACL) is a leading provider of pathology services in Australia. The company operates a network of laboratories and collection centers across the country, offering a comprehensive range of diagnostic testing services. ACL specializes in areas such as clinical pathology, anatomical pathology, and genetic pathology, serving healthcare professionals, hospitals, medical research institutions, and patients.
How the Company Makes MoneyAustralian Clinical Labs Ltd generates revenue primarily through the provision of pathology services. The company's key revenue streams include fees charged for diagnostic and testing services provided to healthcare providers, hospitals, and patients. ACL's extensive network of laboratories and collection centers ensures a wide reach and accessibility, catering to both routine and specialized testing needs. The company may also engage in partnerships with medical institutions and research organizations, contributing to its earnings through collaborative projects and specialized testing services. Additionally, government healthcare programs and private health insurance reimbursements are significant factors that support ACL's revenue generation.

Australian Clinical Labs Ltd Financial Statement Overview

Summary
Australian Clinical Labs Ltd shows a mixed financial performance. Revenue and profitability have been declining, impacting income statement metrics. The balance sheet displays high leverage, which may pose risks if profitability doesn't improve. However, strong cash flow generation offers some stability and flexibility in managing financial obligations. Overall, the company exhibits operational efficiency but must address revenue generation and cost management to enhance financial health.
Income Statement
65
Positive
The company's revenue has been declining from its peak in 2022, and the gross profit margin has also decreased from 79% in 2022 to 36% in 2024. The net profit margin has decreased significantly from 18% in 2022 to 3.5% in 2024. However, the company has maintained a positive EBIT and EBITDA margin, indicating some operational efficiency. The decline in profit margins suggests potential challenges in cost management or pricing power.
Balance Sheet
70
Positive
The debt-to-equity ratio is relatively high at 1.74, indicating a significant level of leverage. However, the company has a positive equity ratio of 30%, suggesting a reasonable buffer of assets over liabilities. Return on equity has decreased from 76.7% in 2021 to 13.5% in 2024, reflecting reduced profitability on shareholder investment. The high leverage could pose risks if earnings continue to decline.
Cash Flow
75
Positive
Operating cash flow remains strong despite a decline in net income, with a high operating cash flow to net income ratio of 6.67 in 2024. Free cash flow has been positive and growing, with a free cash flow to net income ratio of 6.39. This indicates good cash generation capability, which could help in managing debt and funding operations.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue728.27M689.73M692.10M989.30M641.31M487.53M
Gross Profit265.75M247.36M566.02M781.71M521.73M85.04M
EBITDA79.99M169.65M184.93M372.75M196.67M116.30M
Net Income30.67M23.93M35.90M178.24M60.37M41.26M
Balance Sheet
Total Assets585.09M593.06M578.91M628.04M474.70M366.05M
Cash, Cash Equivalents and Short-Term Investments21.57M26.84M19.95M26.37M35.23M35.28M
Total Debt315.32M308.90M316.32M262.38M294.26M221.21M
Total Liabilities415.98M415.30M406.24M395.49M392.79M297.06M
Stockholders Equity168.72M177.53M172.42M232.44M81.90M68.99M
Cash Flow
Free Cash Flow160.47M153.09M136.75M262.83M144.36M92.36M
Operating Cash Flow167.16M159.59M143.68M284.09M153.86M101.74M
Investing Cash Flow-111.00K-7.25M-12.18M-72.04M-6.08M-9.96M
Financing Cash Flow-171.31M-146.14M-137.88M-220.91M-147.37M-60.92M

Australian Clinical Labs Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.82
Price Trends
50DMA
2.83
Positive
100DMA
2.93
Negative
200DMA
3.23
Negative
Market Momentum
MACD
<0.01
Negative
RSI
58.55
Neutral
STOCH
73.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACL, the sentiment is Positive. The current price of 2.82 is above the 20-day moving average (MA) of 2.80, below the 50-day MA of 2.83, and below the 200-day MA of 3.23, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.55 is Neutral, neither overbought nor oversold. The STOCH value of 73.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ACL.

Australian Clinical Labs Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
AU$13.82B24.556.86%3.78%10.15%6.20%
69
Neutral
AU$553.82M18.3218.39%4.43%7.80%99.87%
58
Neutral
£4.85B6.57-62.36%101.97%34.03%6.31%
53
Neutral
AU$998.11M110.291.14%2.16%7.83%―
46
Neutral
AU$580.91M―-4.46%―-7.82%98.08%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ACL
Australian Clinical Labs Ltd
2.87
0.34
13.44%
AU:HLS
Healius Limited
0.82
-0.26
-24.19%
AU:SHL
Sonic Healthcare Limited
28.32
2.66
10.37%
AU:IDX
Integral Diagnostics Ltd.
2.72
0.30
12.40%

Australian Clinical Labs Ltd Corporate Events

Australian Clinical Labs Announces New Director Appointment
Jun 20, 2025

Australian Clinical Labs Ltd has announced the appointment of Stephen Roche as a director, effective from June 20, 2025. The announcement indicates that Roche currently holds no relevant interests in securities, suggesting a fresh start in his role, which may impact the company’s governance and strategic direction.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Appoints Stephen Roche as New Board Chair
Jun 20, 2025

Australian Clinical Labs Limited has announced the appointment of Stephen Roche as a new independent non-executive director, who will transition to the role of Chair of the Board by August 2025. Roche brings extensive strategic and operational experience from various sectors, including healthcare, retail, and consumer goods, which is expected to strengthen ACL’s board and support its mission of improving patient outcomes through innovative pathology services.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Mitsubishi UFJ Financial Group Increases Stake in Australian Clinical Labs
Jun 19, 2025

Australian Clinical Labs Ltd has announced a change in the substantial holding of its shares, with Mitsubishi UFJ Financial Group, Inc. increasing its voting power from 5.01% to 6.08%. This change in shareholding could impact the company’s governance and strategic decisions, potentially influencing its market position and stakeholder interests.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Change in Substantial Holder Interests at Australian Clinical Labs
Jun 18, 2025

Australian Clinical Labs Ltd has announced a change in the interests of a substantial holder, First Sentier Investors. The change affects the voting power and relevant interests in the company’s shares, with implications for the control and management of voting rights. This development could impact the company’s governance and influence its strategic decisions, as substantial holders play a significant role in shaping corporate policies.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Issues Unquoted Equity Securities for Employee Incentives
Jun 17, 2025

Australian Clinical Labs Ltd announced the issuance of unquoted equity securities as part of an employee incentive scheme. This move involves the issuance of service rights and performance rights, which are not intended to be quoted on the ASX, indicating a strategic step to enhance employee engagement and retention.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Issues New Equity Securities
Jun 17, 2025

Australian Clinical Labs Ltd announced the issuance and conversion of unquoted equity securities, specifically 59,046 ordinary fully paid shares, as part of its ongoing financial operations. This move reflects the company’s strategic efforts to manage its equity structure, potentially impacting its market positioning and offering implications for its stakeholders.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Ltd Issues New Equity Securities
Jun 17, 2025

Australian Clinical Labs Ltd announced the issuance and conversion of unquoted equity securities, specifically 15,662 ordinary fully paid shares. This move is part of the company’s ongoing financial management and could impact its capital structure, potentially influencing its market positioning and stakeholder interests.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Announces Change in Substantial Holder Interests
Jun 11, 2025

Australian Clinical Labs Ltd has announced a change in the interests of a substantial holder, Regal Funds Management Pty Ltd and its associates, in the company’s voting securities. This change reflects a shift in the voting power held by Regal Funds Management, which could impact the company’s governance and decision-making processes, potentially influencing its strategic direction and stakeholder interests.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Allan Gray Australia Increases Stake in Australian Clinical Labs
Jun 11, 2025

Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Australian Clinical Labs Ltd from 9.90% to 10.95%. This change in substantial holding reflects a strategic move by Allan Gray Australia, potentially impacting the company’s governance and influencing its strategic direction.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Allan Gray Australia Increases Stake in Australian Clinical Labs
Jun 5, 2025

Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Australian Clinical Labs Ltd from 8.79% to 9.90%. This change in substantial holding reflects a strategic move by Allan Gray Australia, potentially impacting the company’s shareholder dynamics and signaling confidence in the company’s market position.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Allan Gray Australia Increases Stake in Australian Clinical Labs
Jun 3, 2025

Allan Gray Australia Pty Ltd, a substantial holder in Australian Clinical Labs Limited, has increased its voting power from 7.50% to 8.79% as of May 30, 2025. This change in interest may influence the company’s governance and strategic decisions, potentially impacting stakeholders and the company’s market positioning.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates on Buy-Back Program
May 30, 2025

Australian Clinical Labs Limited has announced an update regarding its ongoing on-market buy-back program. The company reported that it bought back a total of 200,000 ordinary fully paid securities on the previous day, adding to a cumulative total of 5,842,629 securities repurchased. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Continues Share Buy-Back Program
May 28, 2025

Australian Clinical Labs Ltd has announced an update on its ongoing on-market buy-back program. As of May 29, 2025, the company has repurchased a total of 5,842,629 ordinary fully paid securities, including 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Ltd Updates on Share Buy-Back Program
May 26, 2025

Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. As of the latest notification, the company has repurchased a total of 5,692,629 ordinary fully paid securities, including 250,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Announces Cessation of Securities
May 23, 2025

Australian Clinical Labs Ltd announced the cessation of 750,000 ordinary fully paid securities due to an on-market buy-back, effective May 19, 2025. This move is part of the company’s capital management strategy, potentially impacting its share value and signaling a focus on optimizing shareholder returns.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Ltd Updates on Share Buy-Back Program
May 19, 2025

Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company has repurchased a total of 250,000 ordinary fully paid securities on the previous day, adding to the cumulative total of 5,192,629 securities bought back to date. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Ltd Updates on Share Buy-Back Program
May 16, 2025

Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company reported that it has bought back a total of 4,892,629 securities prior to the previous day and an additional 300,000 securities on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates on Share Buy-Back Progress
May 14, 2025

Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program, revealing that it bought back 300,000 ordinary fully paid securities on the previous day, adding to a total of 4,592,629 securities repurchased before that day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Allan Gray Australia Increases Stake in Australian Clinical Labs
May 14, 2025

Allan Gray Australia Pty Ltd, acting as an investment manager for various funds, has increased its voting power in Australian Clinical Labs Ltd from 6.49% to 7.50% as of May 12, 2025. This change in substantial holding indicates a growing interest and influence in the company, potentially impacting its governance and strategic decisions.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Regal Funds Management Increases Stake in Australian Clinical Labs
May 9, 2025

Australian Clinical Labs Ltd has announced a change in the substantial holding of its shares, with Regal Funds Management Pty Limited and its associates now holding a significant interest. This change in voting power indicates a shift in shareholder dynamics, potentially impacting the company’s strategic decisions and market positioning.

Australian Clinical Labs Updates on Share Buy-Back Program
May 7, 2025

Australian Clinical Labs Ltd announced an update on their ongoing share buy-back program, revealing that a total of 4,442,629 ordinary fully paid securities have been bought back to date. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and stakeholder interests.

Australian Clinical Labs Updates on Securities Buy-Back
May 5, 2025

Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of the latest notification, the company has bought back a total of 4,274,630 securities, with 150,000 purchased on the previous day. This buy-back initiative may impact the company’s stock value and shareholder equity, reflecting a strategic move to manage capital and potentially enhance shareholder returns.

Australian Clinical Labs Updates on Market Buy-Back Program
May 1, 2025

Australian Clinical Labs Ltd has announced an update on its ongoing on-market buy-back program. The company reported that it bought back 146,130 ordinary fully paid securities on the previous day, adding to a total of 3,978,500 securities bought back prior to that. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Australian Clinical Labs Ltd Updates on Buy-Back Program
May 1, 2025

Australian Clinical Labs Ltd has announced a daily update on its ongoing on-market buy-back program. The company has repurchased a total of 3,978,500 ordinary fully paid securities, with 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Director Michael Alscher Steps Down from Australian Clinical Labs
Apr 30, 2025

Australian Clinical Labs Limited announced the cessation of Michael Thomas Alscher as a director, effective April 30, 2025. Alscher, who held interests in 280,502 ordinary shares through XYZ Services Pty Limited as trustee for the 3C Trust, will no longer be part of the company’s board. This change in directorship might impact the company’s governance and strategic direction, potentially affecting stakeholders and market perception.

Australian Clinical Labs Updates on Share Buy-Back Progress
Apr 30, 2025

Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program, with a total of 3,678,500 ordinary fully paid securities bought back before the previous day and an additional 150,000 securities acquired on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Australian Clinical Labs Updates on Share Buy-Back Progress
Apr 29, 2025

Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. As of April 29, 2025, the company has repurchased a total of 3,678,500 ordinary fully paid securities, including 224,731 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Mitsubishi UFJ Financial Group Acquires Substantial Holding in Australian Clinical Labs
Apr 28, 2025

Australian Clinical Labs Limited has announced a significant development involving Mitsubishi UFJ Financial Group, Inc., which has acquired a substantial holding in the company. This acquisition gives Mitsubishi UFJ Financial Group a 5.01% voting power in Australian Clinical Labs, potentially influencing the company’s governance and strategic decisions. The involvement of a major financial entity like Mitsubishi UFJ Financial Group could impact the company’s market positioning and stakeholder interests.

Australian Clinical Labs Updates on Share Buy-Back Progress
Apr 28, 2025

Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company reported that it bought back a total of 21,950 ordinary fully paid securities on the previous day, adding to the cumulative total of 3,431,819 securities repurchased. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Mitsubishi UFJ Financial Group Ceases Substantial Holding in Australian Clinical Labs
Apr 24, 2025

Mitsubishi UFJ Financial Group, Inc. has ceased to be a substantial holder in Australian Clinical Labs Limited as of April 24, 2025. This change in shareholding, involving multiple transactions of ordinary shares controlled by Morgan Stanley, could impact the company’s market dynamics and investor relations, reflecting a shift in stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025